$16.70
+0.17%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$16.75
From 52W high−20.78%
Volume2171.00
Market cap$57.23M
P/E (TTM)5.1x
P/S (TTM)0.8x
Div yield—
Key dataOct 19, 2026
Open
$16.75
From 52W high
−20.78%
Volume
2171.00
Market cap
$57.23M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.2x
P/E (TTM)
5.1x
RSI (14)
41.7
MomentumView details →
1D Return
+0.17%
YTD Return
+76.50%
SummaryUpdated Jun 1, 2026
Fortress Biotech, Inc. (NASDAQ:FBIO) is a biopharmaceutical company founded in 2006 and originally incorporated as Coronado Biosciences before changing its name in April 2015. Based in Bay Harbor Island, New York, the company has evolved from its early focus on inflammatory bowel disease treatments to become a diversified biotechnology enterprise that both develops novel therapeutics and commercializes approved pharmaceutical products. The company operates through a unique business model that combines immediate revenue generation from marketed dermatology products with a robust pipeline of experimental treatments spanning oncology, rare diseases, and gene therapies.
Similar companies
Latest newsMore news →
Crystalys Therapeutics announced a $130 million Series B financing to support late-stage global development and commercialization preparation for dotinurad.67d agoFortress Biotech, Inc. held its Q2 2026 earnings call on August 12, 2026.68d agoCrystalys Therapeutics closed a $130 million Series B financing to support clinical development of dotinurad for gout.84d ago